相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial
Daniel J. Khalaf et al.
EUROPEAN UROLOGY (2019)
Symptoms and Impacts in Metastatic Castration-Resistant Prostate Cancer: Qualitative Findings from Patient and Physician Interviews
Stefan Holmstrom et al.
PATIENT-PATIENT CENTERED OUTCOMES RESEARCH (2019)
Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer
Alicia K. Morgans et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial
Kim N. Chi et al.
LANCET ONCOLOGY (2018)
Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
Joseph M. Unger et al.
JOURNAL OF PATIENT-REPORTED OUTCOMES (2018)
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study
S. Nilsson et al.
ANNALS OF ONCOLOGY (2016)
Patient-reported outcomes in metastatic castration-resistant prostate cancer
Lesley Fallowfield et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science
N. Nussbaum et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2016)
Analysis: A patient-level data meta-analysis of standard-of-care treatments from eight prostate cancer clinical trials
N. Geifman et al.
SCIENTIFIC DATA (2016)
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot et al.
LANCET ONCOLOGY (2015)
The Project Data Sphere Initiative: Accelerating Cancer Research by Sharing Data
Angela K. Green et al.
ONCOLOGIST (2015)
Comparative Effectiveness of Mitoxantrone Plus Prednisone Versus Prednisone Alone in Metastatic Castrate-Resistant Prostate Cancer After Docetaxel Failure
Angela K. Green et al.
ONCOLOGIST (2015)
Health-related quality of life in menwith metastatic castration-resistant prostate cancer
Abigail Gee et al.
EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH (2015)
Updated Prognostic Model for Predicting Overall Survival in First-Line Chemotherapy for Patients With Metastatic Castration-Resistant Prostate Cancer
Susan Halabi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Effect of abiraterone acetate treatment on the quality of life of patients with metastatic castration-resistant prostate cancer after failure of docetaxel chemotherapy
Stephen Harland et al.
EUROPEAN JOURNAL OF CANCER (2013)
Project Data Sphere to Make Cancer Clinical Trial Data Publicly Available
Karyn Hede
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial
Ethan Basch et al.
LANCET ONCOLOGY (2013)
Minimal clinically important differences in the brief pain inventory in patients with bone metastases
Karrie Wong et al.
SUPPORTIVE CARE IN CANCER (2013)
Constructing a Conceptual Framework of Patient-Reported Outcomes for Metastatic Hormone-Refractory Prostate Cancer
David T. Eton et al.
VALUE IN HEALTH (2010)
Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy-Prostate: Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer
David Cella et al.
VALUE IN HEALTH (2009)
The measurement of pain from metastatic bone disease: Capturing the patient's experience
Charles S. Cleeland
CLINICAL CANCER RESEARCH (2006)
Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance
HEALTH AND QUALITY OF LIFE OUTCOMES (2006)
A retrospective study of the time to clinical endpoints for advanced prostate cancer
N Sharifi et al.
BJU INTERNATIONAL (2005)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
